表紙:頸部ジストニアの世界市場-2023年~2030年
市場調査レポート
商品コード
1352136

頸部ジストニアの世界市場-2023年~2030年

Global Cervical Dystonia Market - 2023-2030

出版日: | 発行: DataM Intelligence | ページ情報: 英文 186 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=154.36円
頸部ジストニアの世界市場-2023年~2030年
出版日: 2023年09月27日
発行: DataM Intelligence
ページ情報: 英文 186 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

概要

頸部ジストニアは、頭部と頸部に発症する疾患です。頸部ジストニアは頸部の極度の筋収縮を引き起こします。これらの筋収縮は、頭部、頸部、時には肩の不随意運動や不快な姿勢を誘発します。頸部ジストニアは、一般に痙攣性斜頸と呼ばれ、頸部の筋肉に影響を及ぼす局所性ジストニアの一種です。

痙性斜頸、側頭斜頸、前斜頸、後斜頸などの種類があります。頸部の筋肉が過活動になると、体勢に影響を及ぼし、ジストニアの影響を受けていない他の筋肉に痛みやこわばりを誘発することがあります。大半の患者には、理由が発見されていません。しかし、一般的に、頸部ジストニアは、大脳基底核や小脳などの脳の様々な領域の機能とリンクの障害に関連していると考えられています。現在のところ、治療法は知られていませんが、症状を改善する治療法はあります。

頸部ジストニアの症例数の増加、合併、買収、製品イントロダクションを含む市場開拓、認知度の高まりなどが、予測期間における世界の頸部ジストニア市場の成長を後押しすると予想されます。さらに、頸部ジストニアに関する研究活動の活発化、技術の進歩、資金提供なども、予測期間における世界市場の成長に貢献すると予想されます。

ダイナミクス

研究活動の増加

研究活動の活発化は、予測期間中の世界市場の成長を後押しすると予想されます。例えば、韓国のバイオエンジニアリング企業であるDaewoong Pharmaceutical社は、片頭痛および頸部ジストニアにおけるナボタの有効性を実証するために、米国食品医薬品局(FDA)の承認を受けた臨床試験を実施中のボツリヌス毒素製品であるナボタを発表しました。さらに、Clinical Trials.govによれば、現在、ある介入研究では、ボツリヌス毒素注射による頸部ジストニア患者の第一選択治療が活発に評価されており、この治療を長期的に受けている患者の中には、緩和期間が短い者もいます。

さらに、米国神経学会(AAN)の年次総会で発表されたタンパの南フロリダ大学からの報告によると、新しいボツリヌス毒素製剤は、メーカーがスポンサーとなった第III相試験で治療を受けた患者の大多数において、信頼できる16週間、頸部ジストニアの徴候を抑えた、投与されたダキシボツリヌストキシンA(略してDaxi)の投与量に基づくと、ピーク治療効果の少なくとも80%を維持する期間の中央値は20~24週間であり、約3分の2の患者が16週目でも完全な効果の少なくとも80%を維持していました。

資金の増額

ジストニア治療の進歩のために、明確な当局や協会からの資金援助が増加していることも、予測期間における世界市場の成長を後押しすると予想されます。例えば、Dystonia Network of Australia Inc.の最大の目的はジストニア研究に貢献することであり、例えば2021年にDNAはウォーカソン、モーニングティー、植物販売などの運動でジストニア研究のために合計4700ドルの資金を集めました。

さらに、運動障害であるジストニアの発見と治療を強化する研究は、ペロン研究所とフィオナ・スタンレー病院が指導する課題に対して、西オーストラリア州保健省から10万米ドルの資金を引き出しました。センター・フォー・ヘルス+テクノロジー(CHeT)は、米国国防総省から290万米ドルの助成金を得て、さまざまな慢性疾患に関する治療調査のための新しい結果基準を設計しました。これらのツールは、臨床試験で奨励される治療法のメリットを個人が理解するためのプラットフォームを提供することが期待されています。

この調査は、Longitudinal Endpoint Optimization to Provide Assessments of Relevant Drugs(LEOPARD)と名付けられ、ミトコンドリア障害、心筋症、関節リウマチ、ジストニアに対する調査ツールを設計することにより、臨床試験の準備を進めることが期待されています。生命を左右するこれら4つの慢性疾患には、現在、実用的な治療法がほとんどありません。この調査は、国防総省の査読付き医学研究プログラムによって支援されています。このプログラムは、米国の戦闘準備態勢と性能を向上させながら、軍人とその家族、民間人の幸福と活動を強化するために設計されたものです。

有病率の低さ

頸部ジストニアの有病率が低いと、調査が制限され、病態が理解されないため、予測期間中、世界市場の成長の妨げになると予想されます。全米希少疾患機構(National Organization for Rare Disorders, Inc.)によると、頸部ジストニアは痙攣性斜頸とも呼ばれ、脳で発症するまれな神経疾患です。

NIHの推定有病率は10万人あたり5~30例です。NIHの推定有病率は、人口10万人あたり3~9例の頸部ジストニア(CD)です。また、早期発症ジストニア(<20 years)is estimated to be between 0.3 and 5 cases per 100,000, whereas the prevalence of adult-onset(>20歳)の有病率は、10万人当たり0.3~732例です。

神経内科医の労働力不足

広範な神経科医の労働力不足は、予測期間中の世界市場の成長を妨げると予想されます。例えば、英国神経科医協会(ABN)が発表したデータによると、英国の神経科専門医の労働力は予想よりも極端に減少しています。フランスやドイツと比較すると、患者対指導医の比率が健全なロンドンやその近郊でさえ、英国の労働力は大きく劣っています。

そのため、ジストニアの患者は、ジストニアを理解し治療するための専門的な訓練を受けた医療従事者の不足に通常遭遇します。この欠乏は、患者が診断を受けるのに長期間待たされること、BoNTを注射する臨床スタッフが非常に少ないこと、新しい訓練を受けた注射医を集めるのに時間がかかりすぎることを示しています。一般的に、治療には長い待ち時間がかかり、CD患者の40%までが、有効性の不十分さを感じて長期のBoNT療法を中止しています。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 研究活動の増加
      • 資金の増額
    • 抑制要因
      • 有病率の低さ
      • 神経内科医の労働力不足
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析
  • 特許分析
  • 技術動向
  • エンドユーザー動向
  • SWOT分析
  • ロシア・ウクライナ戦争の影響
  • DMIの見解

第6章 COVID-19分析

第7章 タイプ別

  • 斜頸
  • 後斜頸
  • 前肩甲介
  • レトロコリス
  • その他

第8章 治療の種類別

  • 薬物療法
    • 抗コリン薬
    • ベンゾジアゼピン系
    • 筋弛緩薬
    • テトラベナジン
    • その他
  • ボトックス注射
  • その他

第9章 エンドユーザー別

  • 病院
  • 専門クリニック
  • 学術研究センター
  • その他

第10章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋
  • 中東・アフリカ

第11章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第12章 企業プロファイル

  • Allergan Inc.
    • 企業概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な動向
  • Boston Scientific Corporation
  • Tercica Inc.
  • US World Meds
  • Merz Pharmaceuticals
  • AEON Biopharma
  • Revance Therapeutics Inc.
  • Galderma SA
  • Ipsen Pharma
  • AbbVie Inc.

第13章 付録

目次
Product Code: PH6878

Overview

Cervical Dystonia is a distinct condition that involves the head and neck. Cervical dystonia elicits extreme muscle contractions in the neck. These muscle contractions induce involuntary actions and uncomfortable positions of the head, neck, and occasionally shoulders. Cervical Dystonia generally referred to as spasmodic torticollis, is a distinct kind of focal dystonia that impacts the muscles of the neck.

It manifest in different types as torticollis, laterocollis, anterocollis and retrocollis. As the muscles of the neck are hyperactive, the individual's stance may be impacted inducing pain and stiffness in other muscles not impacted by the dystonia. For the majority of individuals, no reason is discovered. Nevertheless, it is typically assumed that cervical dystonia is linked to difficulty with the functioning and links of various regions of the brain such as the basal ganglia and cerebellum. Presently there is no known cure, but there are therapies that aid with the symptoms are available.

The growing cases of cervical dystonia, market developments including mergers, acquisitions, products introductions, growing awareness among other factors are expected to boost the global cervical dystonia market growth in the forecast period. Further, the growing research activities, technological advancements and with fundings in cervical dystonia are also expected to contribute to the global market growth in the forecast period.

Dynamics

Increasing Research Activities

The increasing research activities are expected to boost the global market growth during the forecast period. For instance, Daewoong Pharmaceutical, a bioengineering corporation in South Korea, declared that its Nabota, a botulinum toxin product underway the U.S. Food and Drug Administration (FDA) approved clinical trials to demonstrate the effectiveness of Nabota in migraine and cervical dystonia. Moreover, according to Clinical Trials.gov presently one interventional investigation is actively evaluating the first line of treatment for cervical dystonia individuals with botulinum toxin injections, with some patients receiving this treatment long-term experiencing a short duration of relief.

Further, according to the reports from the University of South Florida in Tampa presented at the American Academy of Neurology's (AAN) annual meeting, a new botulinum toxin formulation held cervical dystonia signs at bay for a reliable 16 weeks in the majority of individuals treated in a manufacturer-sponsored phase III trial, Median time to preserve at least 80% of the peak therapy effect was 20-24 weeks, based on the dosage of daxibotulinumtoxinA (Daxi for short) administered, and around two-thirds of individuals still maintained at least 80% of the full effect at week 16.

Increasing Fundings

The increasing funding from distinct authorities and associations to advance dystonia therapies is also expected to boost the global market growth in the forecast period. For instance, the Dystonia Network of Australia Inc.'s foremost purpose has been to contribute to the dystonia study, for instnace, in 2021 DNA raised a total of $4700 funds for dystonia study with movements such as a walkathon, morning tea, and plant sale.

Moreover, a study to enhance the detection and therapy of the movement disorder, dystonia, has drawn $100,000 in funding from the WA Department of Health for an assignment guided by Perron Institute and Fiona Stanley Hospital. The Center for Health+Technology (CHeT) obtained a $2.9 million grant from the U.S. Department of Defense to design novel result criteria for usage in therapeutic investigations concerning a spectrum of chronic conditions. These tools are expected to deliver a platform for individuals to deliver an understanding of the merit of encouraging therapies in clinical trials.

The investigation, entitled Longitudinal Endpoint Optimization to Provide Assessments of Relevant Drugs (LEOPARD), is expected to advance clinical study readiness by designing research tools for mitochondrial disorder, cardiomyopathy, rheumatoid arthritis, and dystonia. There are presently few practical remedies obtainable for these four life-altering, chronic conditions. The investigation is being supported by the Defense Department's Peer Reviewed Medical Research Program, which was designed to enhance the well-being and operation of military personnel, their families, and civilians while enhancing U.S. combat readiness and performance.

Low Prevalence of the Condition

The low prevalence of cervical dystonia is expected to hamper the global market growth during the forecast period, as low prevalence restricts the research and lack of condition understanding. According to the National Organization for Rare Disorders, Inc., Cervical dystonia, also comprehended as spasmodic torticollis, is an infrequent neurological condition that develops in the brain.

The NIH estimated prevalence ranges from 5 to 30 cases per 100,000 individuals. The NIH estimated prevalence is 3-9 cervical dystonia (CD) cases per 100,000 population. Also, the prevalence of early-onset dystonia (<20 years) is estimated to be between 0.3 and 5 cases per 100,000, whereas the prevalence of adult-onset (>20 years) dystonia is between 0.3 and 732 cases per 100,000.

Neurologist Workforce Shortage

The extensive neurologist workforce gaps are expected to hamper the global market growth during the forecast. For instance, the data published by the Association of British Neurologists (ABN) indicates that the UK's workforce of adviser neurologists is extremely down than might be anticipated. In comparison to France and Germany, the UK workforce is largely inferior, even in London and the neighboring places where ratios of patient to adviser are sounder.

Thus, individuals with dystonia usually encounter a lack of medical professionals with the professional training to comprehend and treat dystonia. This deficiency indicates individuals are waiting for extended periods to obtain a diagnosis, there are very few clinical staff injecting BoNT, and it takes too long to assemble new trained injectors. Typically, there are long waiting periods for treatment and up to 40% of people with CD discontinue long-term BoNT therapy following a sensed insufficiency of efficacy.

Segment Analysis

The global cervical dystonia market is segmented based on type, therapy type, end-user and region.

Injections of Botulinum Toxin (Botox) Therapy Type Expected to Dominate Market

There is no specific treatment for cervical dystonia, but manifestations can be controlled utilizing a combination of therapies. The symptoms of cervical dystonia (CD) include uncontrollable muscle spasms in the neck which induce awkward poses, discomfort, and discomfort. Following detection, Botulinum NeuroToxin (BoNT) therapy is the acknowledged benchmark of care in individuals with CD. When the dystonic muscles are injected precisely the comfort and quality of life can be considerably improved.

There are currently four brands of Botulinum toxin that have been authorized by the Food and Drug Administration (FDA) for the therapy of individuals with cervical dystonia. There are three brands of botulinum toxin serotype A, enclosing onabotulinumtoxinA (BOTOX, Allergan Inc.) abobotulinumtoxinA (Dysport, Tercica Inc), and incobotulinumtoxinA (Xeomin, Merz Pharmaceuticals). There is one formulation of botulinum toxin type B, rimabotulinumtoxinB (Myobloc, Solstice, US World Meds).

Further, the new product approvals in this segment are contributing to the segment growth in the forecast period. For instance, in August 2023, Revance Therapeutics, Inc. obtained extended approval from the United States (U.S.) Food and Drug Administration (FDA) for DAXXIFY (DaxibotulinumtoxinA-lanm) injection for cervical dystonia treatment in adults. DAXXIFY, powered by Peptide Exchange Technology, was earlier authorized by the FDA for the temporary enhancement of glabellar lines (frown lines) in adults in September 2022.

Geographical Penetration

Increasing Market Developments in North America

The growing prevalence of cervical dystonia in North America is expected to boost the regional market growth in the forecast period. For instance, cervical dystonia impacts individuals of all ethnic backgrounds. The exact incidence or prevalence of cervical dystonia in the general population is unknown but is estimated to be about 60,000 people in the United States.

American Association of Neurological Surgeons, as many as 250,000 people in the United States have dystonia, making it the third most common movement disorder behind essential tremor and Parkinson's disease. The presence of key market players holding the majority of the global market share along with distinct associations supporting research activities are also contributing to the regional market growth in the forecast period. For instance, the Michael J. Fox Foundation supports research to develop better treatments for the 500,000 individuals in North America living with dystonia.

COVID-19 Impact Analysis

During the COVID-19 pandemic, elective and routine examinations and operations were postponed or discontinued because of redirecting aids to additional emergent therapy for extremely sick individuals and to avert the spread and contraction of COVID-19. Further, the workforce was pulled narrow, and healthcare structures witnessed growing turnover rates for full-time and agreement workers, which pushed the system and decreased the capacity to deliver clinical assistance.

One of the losses of these shifts was rare neurological disorders, which have been assisted less frequently all over the globe since the pandemic. Whether considered standard or emergent, the deferral of neurological disorders induced downstream consequences, including the delay in diagnosis and beginning treatment for cervical dystonia inducing a more raised drop in quality of life.

By Type

  • Torticollis
  • Laterocollis
  • Anterocollis
  • Retrocollis
  • Others

By Therapy Type

  • Drug Therapy
    • Anticholinergics
    • Benzodiazepines
    • Muscle Relaxant
    • Tetrabenazine
    • Others
  • Botox Injections
  • Others

By End-User

  • Hospitals
  • Specialty Clinics
  • Academic Research Centers
  • Other

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa

Key Developments

  • In August 2023, Revance Therapeutics, Inc., the United States (U.S.) Food and Drug Administration (FDA) has authorized the first therapeutic indication for DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for cervical dystonia therapy in adults.
  • In September 2022, AEON Biopharma informed positive topline outcomes from the phase-2 clinical investigation of ABP-450 (prabotulinumtoxinA) in treatment of cervical dystonia in adults.

Competitive Landscape

The major global players in the market include Allergan Inc., Boston Scientific Corporation, Tercica Inc, US World Meds, Merz Pharmaceuticals, AEON Biopharma, Revance Therapeutics, Inc., Galderma SA, Ipsen Pharma, and AbbVie Inc. among others.

Why Purchase the Report?

  • To visualize the global cervical dystonia market segmentation based on type, therapy type, end-user and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of cervical dystonia market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key product of all the major players.

The global cervical dystonia market report would provide approximately 61 tables, 65 figures and 186 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Type
  • 3.2. Snippet by Therapy Type
  • 3.3. Snippet by End-User
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing Research Activities
      • 4.1.1.2. Increasing Fundings
    • 4.1.2. Restraints
      • 4.1.2.1. Low Prevalence of the Condition
      • 4.1.2.2. Neurologist Workforce Shortage
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Patent Analysis
  • 5.6. Technology Trend
  • 5.7. End-User Trend
  • 5.8. SWOT Analysis
  • 5.9. Russia-Ukraine War Impact
  • 5.10. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 7.1.2. Market Attractiveness Index, By Type
  • 7.2. Torticollis*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Laterocollis
  • 7.4. Anterocollis
  • 7.5. Retrocollis
  • 7.6. Others

8. By Therapy Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
    • 8.1.2. Market Attractiveness Index, By Therapy Type
  • 8.2. Drug Therapy*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 8.2.3. Anticholinergics
    • 8.2.4. Benzodiazepines
    • 8.2.5. Muscle Relaxant
    • 8.2.6. Tetrabenazine
    • 8.2.7. Others
  • 8.3. Botox Injections
  • 8.4. Others

9. By End-User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.1.2. Market Attractiveness Index, By End-User
  • 9.2. Hospitals*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Specialty Clinics
  • 9.4. Academic Research Centers
  • 9.5. Other

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. UK
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Allergan Inc.*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. Boston Scientific Corporation
  • 12.3. Tercica Inc.
  • 12.4. US World Meds
  • 12.5. Merz Pharmaceuticals
  • 12.6. AEON Biopharma
  • 12.7. Revance Therapeutics Inc.
  • 12.8. Galderma SA
  • 12.9. Ipsen Pharma
  • 12.10. AbbVie Inc.

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us